Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

20184,544 citationsJournal Articlebronze Open Access

Authors

Robert J. Motzer · Memorial Sloan Kettering Cancer Center

Nizar M. Tannir · The University of Texas MD Anderson Cancer Center

Ray McDermott

Osvaldo Arén Frontera · Centro de Estudios Científicos

Bohuslav Melichar · University Hospital Olomouc

Toni K. Choueiri · Brigham and Women's Hospital

Elizabeth R. Plimack · Fox Chase Cancer Center

Abstract

Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previously untreated advanced renal-cell carcinoma. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 214 ClinicalTrials.gov number, NCT02231749 .).

Topics & Keywords

Renal cell carcinoma treatment Cancer Immunotherapy and Biomarkers Pancreatic and Hepatic Oncology Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 378, Issue 14, pp. 1277-1290

DOI: 10.1056/nejmoa1712126

Field-Weighted Citation Impact: 402.98